Chester County News and Community Website
LANGHORNE, PA — Savara Inc. (Nasdaq: SVRA) announced that its management team will participate in two upcoming healthcare conferences in September.
Savara to Present at Two Upcoming Healthcare Conferences Read More LANGHORNE, PA — Savara Inc. (Nasdaq: SVRA) announced that the results of its Phase 3 IMPALA-2 clinical trial for molgramostim, an inhaled therapy for autoimmune pulmonary alveolar proteinosis (autoimmune PAP), …
Savara’s Phase 3 Trial Shows Promising Results for Rare Lung Disease Treatment Read More LANGHORNE, PA — Savara Inc. (Nasdaq: SVRA) announced that three of its abstracts have been accepted for poster presentation at the European Respiratory Society (ERS) Congress 2025, taking place September …
Savara to Present Key Research on Rare Lung Disease at ERS Congress 2025 Read More LANGHORNE, PA — Savara Inc. (Nasdaq: SVRA) reported second-quarter 2025 financial results and outlined key regulatory and business milestones, including plans to resubmit its Biologics License Application (BLA) for MOLBREEVI, …
Savara to Resubmit BLA for Rare Lung Disease Treatment as Losses Widen in Q2 Read More LANGHORNE, PA — Savara Inc. (Nasdaq: SVRA) announced it has granted inducement awards to two new employees.
Savara Inc. Grants Inducement Awards to New Employees with Stock Options & RSUs Read More LANGHORNE, PA — Savara Inc. (Nasdaq: SVRA) has announced receiving a Refuse-to-File (RTF) letter from the U.S. Food and Drug Administration (FDA) for its Biologics License Application (BLA) of MOLBREEVI, …
FDA Requests Additional Data for Savara’s MOLBREEVI Application Read More LANGHORNE, PA —Savara Inc. (Nasdaq: SVRA) announced the grant of inducement awards to five new employees.
Savara Inc. Grants Equity Awards to New Employees Read More LANGHORNE, PA — Savara Inc. (Nasdaq: SVRA), a clinical-stage biopharmaceutical company, announced its management team will host 1×1 meetings and present at the Jefferies Global Healthcare Conference on June 4, …
Savara Inc. to Present at Jefferies Global Healthcare Conference on June 4, 2025 Read More LANGHORNE, PA — Savara Inc. (Nasdaq: SVRA) unveiled significant findings from its Phase 3 IMPALA-2 clinical trial of molgramostim during two poster presentations at the ATS International Conference 2025. The …
Savara Showcases Promising Phase 3 Trial Data for Molgramostim at ATS 2025 Read More LANGHORNE, PA — Savara Inc. (Nasdaq: SVRA) has announced its financial results for the first quarter ending March 31, 2025, alongside significant business updates, including the submission of its Biologics …
Savara Reports Q1 2025 Financial Results and Advances Key Milestones Read More